These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 27382574)
41. The role of incretin hormones and glucagon in patients with liver disease. Junker AE Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096 [TBL] [Abstract][Full Text] [Related]
42. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Cuthbertson J; Patterson S; O'Harte FP; Bell PM Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998 [TBL] [Abstract][Full Text] [Related]
43. The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery. Timmermans M; Topal B; Sanches EE; DE Jongh FW; Cagiltay E; Celik A; Ribeiro R; Parmar C; Ugale S; Proczko M; Stepaniak PS; Buise MP; Severin R; Pouwels S Minerva Endocrinol (Torino); 2022 Dec; 47(4):449-459. PubMed ID: 33759444 [TBL] [Abstract][Full Text] [Related]
45. Oral administration of corn zein hydrolysate stimulates GLP-1 and GIP secretion and improves glucose tolerance in male normal rats and Goto-Kakizaki rats. Higuchi N; Hira T; Yamada N; Hara H Endocrinology; 2013 Sep; 154(9):3089-98. PubMed ID: 23798598 [TBL] [Abstract][Full Text] [Related]
46. Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies. Tanday N; Flatt PR; Irwin N Diabet Med; 2021 Dec; 38(12):e14699. PubMed ID: 34562330 [TBL] [Abstract][Full Text] [Related]
47. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361 [TBL] [Abstract][Full Text] [Related]
48. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Alavi SE; Cabot PJ; Moyle PM Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435 [TBL] [Abstract][Full Text] [Related]
49. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Christensen MB Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187 [TBL] [Abstract][Full Text] [Related]
50. Glucagon-like peptide-1 and control of insulin secretion. Thorens B Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147 [TBL] [Abstract][Full Text] [Related]
51. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells. Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724 [TBL] [Abstract][Full Text] [Related]
52. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)]. Kluz J; Adamiec R Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790 [TBL] [Abstract][Full Text] [Related]
53. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
54. Incretins and other peptides in the treatment of diabetes. Todd JF; Bloom SR Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764 [TBL] [Abstract][Full Text] [Related]
55. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how? Smits MM; Holst JJ Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788 [TBL] [Abstract][Full Text] [Related]
56. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Lee YS; Jun HS Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094 [TBL] [Abstract][Full Text] [Related]
57. Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases. Lyons SA; Beaudry JL Endocrinology; 2023 Sep; 164(11):. PubMed ID: 37823483 [TBL] [Abstract][Full Text] [Related]